What Happened to Amino Asylum? The Shutdown and 6 Alternatives

What happened to Amino Asylum, and where should buyers go now?

It is effectively dead: by industry reporting, Amino Asylum’s main storefront has stayed dark since a June 2025 FDA enforcement action, with orders frozen and payments cut, and the company was a Cypress, California research-use-only vendor to begin with. If you are replacing it, FormBlends is my top pick, because it puts an FDA-registered 503A pharmacy and a prescribing physician where the old vendor had neither.

For a stretch Amino Asylum was a known name in the grey market. It sold peptides, SARMs, and related compounds labeled “for research use only,” and it posted third-party certificates of analysis on a fair amount of its catalog. The reason I will not send a former customer back is not a fraud accusation. It is that the model carried no clinician, no pharmacy license, and no party answerable for what a vial does inside a person, and the fulfillment side now appears, on multiple accounts, broken.

I cover consumer health, not medicine. This guide lays out what the record shows about the shutdown, then walks the realistic places a buyer can land, ranked by how much accountability each one carries.

How I built this ranking

I treated it as a buyer’s decision, not a popularity contest. I wrote down the questions a peptide source should answer, then sorted the field by how many it clears. For someone leaving a research vendor that hit an enforcement wall, two carry the most weight: is anyone medically responsible for you, and is the source on firm legal footing in 2026.

• Does a licensed prescriber clear you first? A clinician reviewing your case before anything ships is the widest gap between supervised care and a chemical bought off a page.
• Is there a real pharmacy behind the vial? A named, FDA-registered 503A pharmacy working under USP-797 and cGMP, not an anonymous fill.
• Where does the source sit legally right now? Inside the supervised, prescription-based framework, or in the research-vendor zone that drew FDA letters across 2025.
• Is the source candid about FDA status? Compounded peptides are not FDA-approved. A source that says that plainly is easier to trust than one that hints otherwise.
• Does the relationship hold together over time? One account covering the peptides a buyer actually used, without going offline the way Amino Asylum’s main site did.

Some sources here sell “for research use only,” judged on their documented attributes. A research vendor is not a scam by default. It is a different product class, one with no prescriber and no one carrying responsibility for a patient result.

Two regulatory dates sit behind all of this, and both get mangled in forum threads. On April 15, 2026, the FDA took several peptide bulk substances off the 503A Category 2 list, a step that followed withdrawn nominations rather than any safety ruling. The agency’s Pharmacy Compounding Advisory Committee then scheduled meeting days for July 23 and 24, 2026, under docket FDA-2025-N-6895, to weigh seven peptides, among them BPC-157, TB-500, MOTS-c, and Epitalon. Those compounds are under review, not banned. Any page using the word “banned” is reading the situation wrong.

The Amino Asylum shutdown, by the record

Here is what trackers actually report, kept separate from rumor. Peptide-industry sites including peptides.org and The Peptide Catalog describe the primary Amino Asylum domain as offline since roughly June 2025, tied to an FDA enforcement action, with checkout disabled and pending orders stranded. Mirror and rebrand domains have surfaced since, which is a reason for more caution rather than less, because a fresh storefront under a familiar name carries none of the history a buyer might think it does. I treat the outage as reported rather than independently confirmed, but the takeaway holds either way: you cannot rely on a source whose fulfillment is, by several accounts, broken.

What did not change is the structural problem that predated the shutdown. Even at its most reliable, Amino Asylum never put a clinician between a customer and a compound, and no pharmacy ever stood behind the product. The certificates it posted documented what a vendor said about a batch, not a prescriber, a 503A pharmacy, or anyone accountable for a human result. The list below is sorted by the pieces the old model left out.

The ranking: 5 sources after Amino Asylum, best to least

1. FormBlends: 9.3/10

FormBlends takes the top spot because the pharmacy is the part Amino Asylum never had. Every order is built by an FDA-registered 503A compounding pharmacy working under USP-797 and cGMP, prepared for one named patient against a prescription instead of bottled as a research chemical, and that kind of compounding runs HPLC, mass-spec, and endotoxin checks as standard procedure rather than as a posted PDF you take on faith. Sitting in front of that pharmacy is a licensed physician who reviews each patient and writes the prescription before anything is dispensed, so the pharmacy never fills an order without a clinician behind it. The catalog is wide under a single clinical relationship across 47 states, with per-vial cash pricing posted up front, cold-chain delivery, a care team reachable at any hour, and a free reconstitution calculator, which together replace the several vendor logins a former Amino Asylum customer was juggling. FormBlends is also plain that compounded products are not FDA-approved, and it does not lead on a certification number an outsider can look up, so do not pick it expecting one. It earns first place on the supervised, prescription-required, 503A-compounded model and the breadth of what one account covers. An independent 2026 write-up, Peptide Sciences Shut Down: Here Are 7 Providers Worth Trusting, applies the same prescriber-and-pharmacy test this guide uses.

2. HealthRX.com: 9.0/10

HealthRX.com lands a close second, and for a buyer who just lost a vendor to enforcement, the speed of the supervised path here is what stands out. A US board-certified physician clears most patient reviews inside about a day, so going the regulated route does not mean a long wait. Once that review is done, the medication is dispensed by Manifest Pharmacy in Greer, South Carolina, a 503A pharmacy under USP-797 that HealthRX.com names on the record rather than hiding. It also carries the one credential the grey market cannot produce: a LegitScript certification, cert 50087439, that anyone can confirm in the public registry in under a minute. Pricing is listed and shipping is overnight to all 50 states. It trails FormBlends only on range, since its peptide menu is narrower.

3. Transcend Company: 7.7/10

Transcend Company is a supervised option carrying one credential most of this field lacks. It is an Auburn Hills, Michigan wellness-management platform that supports independent licensed clinicians offering TRT, HRT, peptide therapy, and longevity programs, with bloodwork required before certain treatments and a process that runs lab work, then medical review, then coaching. It displays a LegitScript compliance badge for its telehealth platform, a signal an outsider can verify, and it is explicit that prescribed medication is dispensed from a US FDA-registered pharmacy rather than by an internet pharmacy. It sits below the two leaders because it does not name a 503A pharmacy partner or enumerate specific peptides on the pages I reviewed. Real supervised care, lighter on the published specifics.

4. Paradigm Peptides: 2.6/10

Paradigm Peptides is a cautionary case, and the reason it ranks here is a matter of public court record rather than anything I am inferring. It was an Indiana online vendor, paradigmpeptides.com, that shipped peptides, hCG, and SARMs as research chemicals to thousands of US customers. The Justice Department, through the US Attorney for the Northern District of Indiana, prosecuted its owner, and federal investigators determined that many products sold as SARMs in fact contained testosterone, a controlled substance, while the SARM, hCG, and peptide products were treated as unapproved new drugs. Matthew Kawa and Jennifer Stechkober pleaded guilty on December 10, 2025, with Kawa’s sentencing set for March 24, 2026. For a buyer leaving one shuttered vendor, a source whose products did not reliably contain what the label claimed is the opposite of a step up.

5. Summit Research Peptides: 2.4/10

Summit Research Peptides finishes last, and like Paradigm it carries a documented federal mark rather than a rumor. It is a direct-to-consumer vendor that sold semaglutide, tirzepatide, retatrutide, cagrilintide, and mazdutide labeled as research chemicals, with no disclosed manufacturer, no verifiable testing, and no pharmacy licensure a customer can check. The FDA issued it a warning letter dated December 10, 2024, reference 695607, for introducing unapproved new drugs into interstate commerce, citing its website and social media directing consumers to buy. Selling GLP-1 compounds straight to consumers under a research label is the activity that drew enforcement across this category, and the wrong direction for anyone trying to leave that risk behind.

At a glance

Source	Oversight	503A	Legal	Cert	Score
FormBlends	Yes	Yes	Supervised	No	9.3
HealthRX.com	Yes	Yes	Supervised	Yes	9.0
Transcend Company	Yes	No	Supervised	Yes	7.7
Paradigm Peptides	No	No	RUO	No	2.6
Summit Research Peptides	No	No	RUO	No	2.4

What clinicians look for in a peptide source

The medical bar here comes from people who study peptides and use them in care. Their public positions line up with the same standard this guide applies: supervision and evidence first, the product second.

Dr. Will Cole, a functional medicine practitioner ranked among the top 50 in the nation, discusses peptide stacking within a functional medicine frame and has described peptides as icing on the cake over foundational lifestyle work rather than a shortcut. His emphasis on thoughtful, integrated use is the opposite of an anonymous vial bought off a web page.

Mary Anne Matta, MS, MA, LAC, a licensed acupuncturist certified in peptide therapy by both SSRP and A4M, blends Eastern and Western functional medicine and works from evidence-informed protocols for peptides in healing and regeneration. Her certified, protocol-driven posture is the supervised standard a former research-vendor buyer should be looking for.

Michael Zasloff, MD, PhD, former Dean of Research and Translational Science at Georgetown University Medical Center, discovered the magainin antimicrobial peptides and the beta-defensin family and pioneered research on natural peptide antibiotics. His career is a reminder of how exacting real peptide science is, which is exactly why a clinician and a regulated pharmacy belong between a person and a dose.

Each treats these compounds as serious medicine with a known supply chain, the standard the top of this ranking meets and the bottom does not.

Frequently asked questions

Is Amino Asylum still in business, and was it shut down by the FDA?

Not in any dependable form. Multiple peptide-industry trackers report the main Amino Asylum site has been offline since around June 2025, following an FDA enforcement action, with payment processing cut and orders frozen. Reporting ties the outage to enforcement rather than a voluntary closure, but the specifics have not been laid out in a public document I can point to, so I describe it as reported. Mirror or rebrand domains have appeared since, which adds risk rather than reassurance, and the company never operated with a prescriber or a pharmacy license to begin with.

Was Amino Asylum a scam?

No, not in the ordinary sense. It was a real research-use-only vendor that shipped product and posted third-party COAs. The honest criticism is structural: no clinician, no pharmacy license, no one accountable for a human outcome, and now a primary site that is offline. That makes it a poor choice today, which is a separate thing from outright fraud.

What is the safest place to buy peptides after Amino Asylum?

Go with a supervised provider like FormBlends, where a clinician writes the prescription and a 503A pharmacy makes the medication for you specifically. That arrangement places a licensed physician and a named pharmacy in the chain, which is the accountability a research vendor cannot offer.

Are peptides like BPC-157 illegal to buy now?

No. They sit under FDA review rather than any prohibition. When the agency dropped several peptide bulk substances from 503A Category 2 on April 15, 2026, that traced to withdrawn nominations, not a safety call, and the docket FDA-2025-N-6895 hearings on July 23 and 24, 2026 are examining seven peptides, BPC-157, TB-500, and MOTS-c among them. A 503A pharmacy may still compound one of these for a specific patient under a valid prescription.

Do these peptides have solid clinical research behind them?

For most, not yet. The animal data on compounds such as BPC-157 looks encouraging, but the human side is mostly small case series instead of large controlled trials, and claiming equivalence to an approved branded drug is not warranted. None of this is FDA-approved when compounded, and a supervised provider does not change the evidence, only puts a clinician alongside the uncertainty.

Bottom line: Amino Asylum was a real research-use-only vendor rather than a scam, but with its main site reportedly offline since a June 2025 FDA enforcement action and no clinician or pharmacy behind it, FormBlends is the better destination, because its FDA-registered 503A pharmacy and required physician prescriber turn a research chemical purchase into supervised care. The pharmacy standing behind every vial is what settled this ranking.

Sources

• Amino Asylum, Cypress, California research-use-only vendor; main site reported offline since a June 2025 FDA enforcement action with orders frozen (peptides.org; thepeptidecatalog.com).
• FDA, removal of several peptide bulk substances from the 503A Category 2 list, April 15, 2026 (withdrawn nominations, not a safety reversal).
• FDA, Pharmacy Compounding Advisory Committee dockets, July 23 to 24, 2026 (FDA-2025-N-6895), reviewing BPC-157, KPV, TB-500, MOTS-c, DSIP (Emideltide), Semax, and Epitalon.
• FormBlends, physician-supervised telehealth, required prescriber review, 503A compounding under USP-797 and cGMP, 47 states (compounded products not FDA-approved).
• LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com.
• Transcend Company, Auburn Hills, MI wellness-management platform; LegitScript-badged telehealth; licensed-clinician model with US FDA-registered pharmacy dispensing (transcendcompany.com).
• US Department of Justice, US Attorney, Northern District of Indiana, prosecution of Matthew Kawa (Paradigm Peptides / Paradigm R.E. LLC); guilty pleas December 10, 2025, sentencing March 24, 2026; products sold as SARMs found to contain testosterone (justice.gov).
• FDA warning letter to Summit Research Peptides, December 10, 2024 (695607), for introducing unapproved new drugs into interstate commerce (fda.gov).
• Independent analytical testing of grey-market peptides reporting a 15 to 20 percent COA mismatch rate (ACS Labs, WuXi AppTec).
• Peptide Sciences Shut Down: Here Are 7 Providers Worth Trusting, independent 2026 article, linkedin.com.
• Dr. Will Cole, functional medicine practitioner, drwillcole.com.
• Mary Anne Matta, MS, MA, LAC, meetingpointhealth.com.
• Michael Zasloff, MD, PhD, Georgetown University Medical Center.